EYPT News & Events

EyePoint announced the independent data safety monitoring committee completed its third scheduled review of the company's pivotal Phase 3 program evaluating Duravyu for wet age-related macular degeneration, recommending both the LUGANO and LUCIA trials continue as planned with no protocol modifications. Interim masked safety data show a continued favorable safety profile, consistent with safety observed in over 190 patients across four completed clinical trials. As of May 2, all active patients in the treatment arm have reached the Week 32 visit, receiving their second DURAVYU dose, with over 35% also receiving a third planned dose at Week 56. LUGANO topline data is on track for mid-2026, with LUCIA to follow shortly after; this is the last anticipated committee review ahead of topline data. "Safety is paramount in retinal disease therapies, and receiving three consecutive positive DSMC recommendations to continue our Phase 3 wet AMD trials without modification reflects the consistency of DURAVYU's safety profile and the rigor of our Phase 3 wet AMD program design," said Ramiro Ribeiro, chief medical officer.

Reports Q1 revenue $696,000, consensus $352,830. "We are entering an important time for EyePoint and the retina community with Phase 3 topline data for DURAVYU in wet AMD expected beginning mid-year with LUGANO topline data and the identical LUCIA trial data readout to follow," said Jay S. Duker, President and Chief Executive Officer of EyePoint. "In parallel, enrollment in our Phase 3 DME program is meeting our ambitious timelines with full enrollment expected in the third quarter of 2026, positioning DURAVYU for pivotal readouts in the two largest multi-billion-dollar retina markets."

EyePoint granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 20,000 shares of EyePoint common stock to six new employees. The stock options were granted on March 13, 2026. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $13.20 per share, the closing price of EyePoint's common stock on March 13, 2026. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint through the applicable vesting dates.